title: [A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy].
abstract: We report a case of a 58-year-old man suffering from advanced colon cancer with liver metastases. After the sigmoidectomy and left lateral segmentectomy, mFOLFOX6+bevacizumab was initiated. The mFOLFOX6+bevacizumab therapy was performed for 15 courses, but it was stopped because of an increase in serum levels of tumor markers(CEA and CA19-9). For the next treatment, FOLFIRI+panitumumab therapy was performed. At the beginning of the second course, he suffered from dyspnea. Computed tomography showed ground-glass opacities and traction bronchiectasis in both lung fields. He was diagnosed with interstitial pneumonitis induced by irinotecan or panitumumab. Corticosteroid therapy consisting of methyl- prednisolone(1 g/day)administered for three days was significantly effective for treating respiratory failure. Two courses of the therapy were performed, and he was discharged without aftereffects. As with other EGFR tyrosine kinase inhibitors, the frequency of interstitial pneumonitis induced by irinotecan in Japan may increase to European and American levels.
authors.affiliation: Dept. of Pulmonary Medicine, Ogaki Municipal Hospital, Japan.
authors.forename: Kenta
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Toshio
authors.initials: T
authors.lastname: Kato
authors.forename: Jo
authors.initials: J
authors.lastname: Shindo
authors.forename: Morihide
authors.initials: M
authors.lastname: Ando
authors.forename: Takashi
authors.initials: T
authors.lastname: Abe
authors.forename: Akira
authors.initials: A
authors.lastname: Shiraki
authors.forename: Harunori
authors.initials: H
authors.lastname: Nakashima
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Yukita
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000628:therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077544:Panitumumab; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D009944:Organoplatinum Compounds; D000077544:Panitumumab; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D008775:Methylprednisolone; D002166:Camptothecin